Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

DiaMedica enrolls final patient in phase DM-83 clinical trial

May 7, 2008

FDA accepts for review Cinryze complete response submission

May 7, 2008

Bayer Schering Pharma to market new low-dose oral contraceptive in Europe

May 7, 2008

Febuxostat receives E.U. marketing authorization for hyperuricemia in gout

May 6, 2008

FDA advisory committee recommends approval of Cinryze for HAE

May 6, 2008

T-2384, a novel antidiabetic agent shows good results in preclinical studies

May 6, 2008

Novel agents with possible use in obesity and other metabolic disorders described in recent patents

May 2, 2008

Recent patents cover new agents for endocrine disorders

May 2, 2008

Merck receives not approvable letter from FDA for MK-0524A

April 30, 2008

Metabasis reports positive results from phase IIa clinical trial of MB-07803 in type 2 diabetes

April 30, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...